Abstract：Abstract: To evaluate the immune safety of recombinant G protein of respiratory syncytial virus(RSV)， purified GCX3C and GCTL proteins were immunized mice with CpG adjuvant by intramuscular injection on 0, 2 and 4 weeks. After immunization, IFN-γ、IL-4 and IgE in mouse lung were detected. 105 pfu RSV was used to challenge the immunized mice. The lungs of challenged mice were performed histologic section for pathological test. IL-4 and IgE in the lung of the GCTLgroup were lower than that of the GCX3C group. INF-γ content and INF-γ/IL-4 ratio of the CpG group and the GCTL+CpG group were significantly higher(P<0.05) than that of other groups. And ELISPOT experiments showed that the CpG adjuvant could increase the number of spleen lymphocytes secreting INF-γ. After virus challenged mice, the lung lesions of PBS group and CpG group were observed and extremely severe. The histological lesion in GCTL+CpG group was more severe than that in GCX3C+CpG group. However, the tissue lesion in GCTL group was much better than that in GCX3C group. The experimental results showed that the recombinant GCTL protein can reduce the Th2 type immune response with good safety and protection against the wild-type RSV challenge.
引用本文:
陈 伟, 张 凝, 乔 磊, 陈卫东, 井申荣. 重组呼吸道合胞病毒G蛋白疫苗的免疫安全性研究[J]. 生命科学研究, 2016, 20(1): 45-49.
CHEN Wei, ZHANG Ning, QIAO Lei, CHEN Wei-Dong, JING Shen-Rong. Study on the Safety of the Recombinant G Protein of Respiratory Syncytial Virus. Life Science Research, 2016, 20(1): 45-49.
2016, Vol. 20 
